All posts by imreal

Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Southeast United States


News Image

With the addition of Jubilant’s Norcross Radiopharmacy to our distribution network, Life Molecular Imaging continues to expand the availability of Neuraceq®, an important diagnostic imaging tool for the detection of beta-amyloid plaques in the brain.

Life Molecular Imaging (LMI) and Jubilant Radiopharma announce today that both companies have entered into a strategic partnership and licensing agreement providing Jubilant Radiopharma with rights to manufacture and distribute Neuraceq® in the Southeast Region of United States.

Jubilant Radiopharma will manufacture Neuraceq® at their PET cyclotron facility which has an adjoining SPECT radiopharmacy in Norcross, GA. The first doses will be available from January 18th, 2023.

Neuraceq® is an approved imaging agent for the detection of beta-amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes of cognitive decline. It is used in clinical routine and is also a powerful imaging biomarker for the appropriate characterisation of subjects enrolled in clinical trials to support drug development in neurodegenerative diseases.

“With the addition of Jubilant’s Norcross Radiopharmacy to our distribution network, Life Molecular Imaging continues to expand the availability of Neuraceq®, an important diagnostic imaging tool for the detection of beta-amyloid plaques in the brain. We are truly excited about this collaboration with Jubilant Radiopharma to make our approved beta-amyloid tracer Neuraceq® even more available to physicians and their patients and to our pharma partners for routine clinical and research use”, said Ludger Dinkelborg, Ph.D., Managing Director at LMI.

“It is a great pleasure to have signed this important manufacturing and distribution agreement with Life Molecular Imaging” – declares Renato Leite, President at Jubilant Radiopharmacies. “Our strategic partnership with LMI will expand the availability of the innovative molecular imaging agent Neuraceq®, to patients in the Southeast contributing to the fight against Alzheimer’s disease and other causes of cognitive decline”.

About Neuraceq® (florbetaben 18F)

Indication

Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.

A negative Neuraceq® scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq® scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq® is an adjunct to other diagnostic evaluations.

Limitations of Use

· A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder.

· Safety and effectiveness of Neuraceq® have not been established for (i) predicting development of dementia or other neurologic conditions and (ii) monitoring responses to therapies.

Important Safety Information

Risk for Image Interpretation and Other Errors

Neuraceq® images should be interpreted independent of a patient’s clinical information. Physicians should receive training prior to interpretation of Neuraceq® images. Following training, image reading errors (especially false positives) may still occur. Additional interpretation errors may occur due to, but not limited to, motion artifacts or extensive brain atrophy.

Radiation Risk

Administration of Neuraceq®, like other radiopharmaceuticals, contributes to a patient´s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. It is important to ensure safe handling to protect patients and health care workers from unintentional radiation exposure.

Most Common Adverse Reactions

In clinical trials, the most frequently observed adverse drug reactions in 872 subjects with 1090 Neuraceq® administrations were injection site reactions, consisting of erythema (1.7%), injection site irritation (1.1%), and pain (3.4%).

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Please visit https://life-mi.com.

About Life Healthcare Group

Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 38 years’ experience in the South African private healthcare sector, and currently operates 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and wellness, occupational health, primary health and emergency medical services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services (MRI, CT, and PET scans) within Europe, operating internationally across 10 countries. Life Molecular Imaging, a division of Alliance is an integrated pharmaceutical business that includes research and development laboratories, access to a network of cyclotrons and radio-pharmacies and imaging facilities, with Life Radiopharma being Alliance’s distributor of radiopharmaceuticals to diagnose many types of diseases. Visit https://www.lifehealthcare.co.za/

About Jubilant Radiopharma

Jubilant Radiopharma (Jubilant Draximage Inc.) is a subsidiary of Jubilant Pharma Limited. The Radiopharma business comprises development, manufacturing and commercializing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of Improving Lives Through Nuclear Medicine on a global scale through Radiopharmaceuticals business with cGMP complaint and ISO 13485 certified manufacturing facilities and distribution through the radiopharmacies business which is the second largest network in the US with 48 radiopharmacies distributing nuclear medicine products to the largest national Group Purchasing Organisations (GPOs), regional health systems, stand-alone imaging centres, cardiologists and hospitals.

For media inquiries

Contact:

Nick Karabatsos, Chief Commercial Officer, Life Molecular Imaging: mailto:n.karabatsos@life-mi.com [n.karabatsos@life-mi.com __title__ null]

Jonathan Pharr, Director of Marketing, Jubilant Radiopharma: mailto:Jonathan.Pharr@jubl.com [Jonathan.Pharr@jubl.com __title__ null]

Share article on social media or email:

Next Gen Diagnostics CEO Paul A. Rhodes Announces Formation of Subsidiary NGD Israel, Ltd.


Next Gen Diagnostics, which is bringing whole genome sequencing to clinical microbiology, announced today the formation of its subsidiary NGD Israel, Ltd., to offer low-cost pathogen sequencing, transmission detection, and sequence-based infectious disease diagnostics to Israel.

Next Gen Diagnostics, which is bringing whole genome sequencing to clinical microbiology, announced today the formation of its subsidiary NGD Israel, Ltd., to offer low-cost pathogen sequencing, transmission detection, and sequence-based infectious disease diagnostics to Israel. NGD’s pathogen sequencing lab will be centrally located to facilitate providing rapid pathogen sequencing service to customers across Israel. NGD will offer a complete turn-key service including extraction, library preparation, sequencing, and fully validated bioinformatic analysis, at unprecedentedly low cost.

“NGD and its distinguished cofounders have developed and validated among the most advanced and complete automation of bacterial WGS bioinformatics, from quality control and relatedness determination to resistome profiling and antibiotic resistance prediction,” said Paul A. Rhodes, Ph.D., NGD’s founder and CEO. “The entire suite of information, validated in a series of published studies, is provided to users in an intuitive web-based interface that is automatically populated overnight with the information generated from each sequencing run. Our rapid turn-around enables this information to be at the fingertips of infection control and infectious disease services fast enough to have a real-time impact on infection control.”

NGD is able to offer a complete sequencing service at a price below PCR panels because of the cost advantages of its microfluidic sample preparation system. This proprietary system enables library preparation for up to 48 distinct strains to be processed in a disposable the size of a single plate, in a fully automated fashion. An instrument the size of a desktop computer replaces the dining table-sized robots used to automate sample preparation in competing services, with microfluidic reaction chambers less than a uL in volume enabling reduction in the consumption of costly reagents, together greatly reducing sample preparation costs.

“Israel will be one the first markets in which NGD will offer its complete sample preparation-sequencing-bioinformatics service,” noted Dr. Rhodes. “Israel is well-known to be an early adopter of medical system advances, as it demonstrated during Covid. NGD’s service will offer the chance to use prospective sequencing of pathogens to detect transmission of antibiotic resistant infection.”

“NGD’s bioinformatic system was applied at Addenbrooke’s Hospital in Cambridge in tandem with prospective sequencing to detect transmission and guide intervention, where it was documented to have stopped an outbreak ,” said Dr. Rhodes. “The low cost of the service makes prospective sequencing practical as the new paradigm for the detection of transmission and prevention of outbreak in hospitals, where transmission of drug resistant infection is such an appalling problem.”

About Next Gen Diagnostics

NGD, founded by Dr. Paul A. Rhodes along with Sanger Institute group leaders, has built and validated world-leading automation of pathogen bioinformatics enabling high throughput low cost clinical use of WGS. In addition, NGD holds the exclusive rights to a unique microfluidic sample preparation system for clinical and commercial applications of pathogen WGS. NGD offers a high volume turn-key sequencing services to enable detection of transmission in hospitals, and is working with leading collaborators in the US, Europe and Israel to be among the first to bring WGS-based regulated diagnostics to patient care. NGD is based in the US, with subsidiaries based in Cambridge, UK and in Israel.

For press inquiries, please contact: press@nextgen-dx.com

Share article on social media or email:

Houston Housing Authority Reopens Public Housing Waitlist for First Time Since 2018


News Image

“The last thing people in crisis need is the added stress of navigating a complicated application process. At the end of the day, our priority is transforming the lives of those in need,” HHA President and CEO David A. Northern, Sr.

Houston Housing Authority (HHA) is reopening its public housing waitlist on Sunday, Jan. 15 at 12:00 p.m. CT through Wednesday, Feb. 15 at 4:00 p.m. CT. The agency temporarily closed its waitlist in 2018, in response to Houston’s growing affordable housing shortage. All eligible low-income households, seniors, veterans, and persons with disabilities are encouraged to apply online at housingforhouston.com or in person at HHA’s Administrative Office.

“Many families are either struggling to find affordable housing or remain housed with the highly-competitive state of our current housing market,” HHA Board Chairman LaRence Snowden said. “Reopening the waitlist enables us to provide more support and solutions to those in need.”

The newly-enhanced waitlist application and online portal were designed to help streamline the process for applicants, providing greater accessibility and efficient access for those in need. The waitlist and portal will also include the ability to apply to multiple HHA properties using a single application. Applicants may choose from the following HHA properties: Cuney Homes, Ewing, Kennedy Place, Independence Heights, Heatherbrook, Lincoln Park, Bellerive, Irvington Village, Kelly Village, and Lyerly. For the first time, applications will be available in English, Spanish, Vietnamese, Mandarin, Swahili, and Korean.

“Houston is experiencing one of the nation’s worst affordable housing shortages right now,” HHA President and CEO David A. Northern, Sr. said. “The last thing people in crisis need is the added stress of navigating a complicated application process. At the end of the day, our priority is transforming the lives of those in need.”

About Houston Housing Authority: HHA provides affordable homes and services to more than 60,000 low-income Houstonians, including more than 17,000 families housed through the Housing Choice Voucher Program as well as another 4,200 living in 19 public housing and tax credit developments around the city. HHA also administers one of the nation’s largest voucher programs exclusively serving homeless veterans. More information about the Houston Housing Authority can be found at http://www.housingforhouston.com.

Share article on social media or email:

Experience Daily Love and Affirmation with Pink Kisses App


"Experience the Joy of Daily Affirmations with Pink Kisses App, Where You Can Customize Your Simulator Sweetie"

Customize Your Virtual Sweetheart with Pink Kisses App

“We see the Pink Kisses app as something fun, flirty, and not to be taken too seriously. It’s really you sending yourself a fun, loving message each day,” says Alison Chace, the actress and entrepreneur behind Pink Wisdom.

Pink Wisdom, a premier digital destination for career and relationship advice, is excited to announce the launch of their first app, Pink Kisses. This unique app sends one or two positive texts per day to a user’s phone for only $20.99 a year.

Pink Kisses sends users daily fun and flirty messages, such as “I woke up thinking about you” or “How do you manage to look so stunning every day?” Users can name the sender whatever they desire, whether it’s the name of their crush, a friend they’re secretly daydreaming about, or even their own name as a reminder to treat themselves with kindness. Although the app isn’t designed to provide a direct reply, users are free to respond if they wish. Pink Kisses is available in English, Mandarin, and Japanese.

The Pink Kisses app incorporates the idea that receiving a text message can release dopamine, which can improve one’s mood and well-being. Although not scientifically proven, this feature is intended for those interested in digital self-care and is not intended to replace real-life relationships.

Pink Kisses isn’t quite an AI partner, and isn’t quite an affirmations app — it lives somewhere between the two, in a fanciful home all its own. Alison Chace, the actress and entrepreneur behind Pink Wisdom, sees the app as a lighthearted novelty item — and also as a wink reminding the user is worthy of love, whether coupled up or soaring on her own.

According to Pink Wisdom, their new app, Pink Kisses, can help improve relationships. Users can send the texts to themselves or forward them to a loved one as a way to strengthen their bond and deepen their connection.

Pink Kisses is available for iOS devices and can be downloaded for free for the first three days, with a subscription of $2.49 per month or $20.99 per year thereafter.

“Pink Wisdom’s tagline is ‘sugar, spice, and expert advice,’ and we especially love the ‘spice’ part,” says Alison Chace, the actress and entrepreneur behind Pink Wisdom. “We see the app as something fun, flirty, and not to be taken too seriously. It’s really you sending yourself a fun, loving message each day.”

Pink Kisses is the perfect way to celebrate Valentine’s Day (or any day) and practice digital self-care in a fun and lighthearted way.

How does it work?

Download the Pink Kisses app from the Apple Store.

Sign up to receive one or two texts each day.

Name the Simulator Sweetie who will send the juicy messages.

User begins receiving Pink Kisses the following day.

Contact Pink Wisdom founder Alison Chace at alison@pinkwisdom.com or 917-821-8931 for more information, or visit https://www.pinkwisdom.com/pink-kisses and follow @pinkwisdomdotcom,

@pinkkissesapp, and @alisonchace on social media for all the latest updates

Share article on social media or email:

SHRM National President & CEO to Keynote GOSHRM’s Inaugural Mental Health Forum, January 24; GOSHRM Wins Two Awards for Community Impact on Opioid Crisis


Color photo of SHRM President and CEO, Johnny C. Taylor, Jr., SHRM-SCP

SHRM President and CEO, Johnny C. Taylor, Jr., SHRM-SCP

“At SHRM, our goal is to show that workplace environments with belonging and mental health support are good for employees and organizations. It’s never been more important to build inclusive, empathetic and supportive workplace cultures given the current mental health crisis,” said Taylor.

The Greater Orlando Society for Human Resource Management (GOSHRM) will host its first Mental Health Forum on Tuesday, January 24 at the Wyndham Orlando Resort and Conference Center in Kissimmee, FL. The Forum is “A Well-being Gut Check” for HR and medical professionals seeking best practices to tackle mental health challenges in today’s stressful, post-pandemic workplace.

GOSHRM’s goal in presenting the Mental Health Forum is to provide increased awareness and support for mental health concerns plaguing the current workforce. This highly anticipated event has limited capacity of 250 attendees and is expected to sell out. Attendees receive 4.5 SHRM and HRCI recertification credits. Register here.

The theme was carefully chosen by GOSHRM’s Board of Directors because of increased concerns and stigma associated with mental health issues on the job. “There is a real hesitancy among the HR community to talk openly about these issues,” said GOSHRM President, Pamela J. McGee, SHRM-SCP, PHR, MBA. “Our Mental Health Forum is designed to help break the silence and create a workplace culture that supports those who struggle.”

The January 24th event features a celebrity keynote, an intimate fireside chat and power-packed panel sessions from a diverse group of distinguished subject matter experts. During his Keynote address, SHRM President and CEO, Johnny C. Taylor, Jr., SHRM-SCP, will talk about “Workplace Culture: Caring About the Whole Self.”

“At SHRM, our goal is to show that workplace environments with belonging and mental health support are good for both employees and organizations. It’s never been more important to build inclusive, empathetic and supportive workplace cultures given the current mental health crisis happening right now,” said Taylor. “Since we began this conversation last year, I am proud that SHRM and the SHRM foundation have taken this commitment forward. We aim to move the conversation into action—working toward solutions for a better tomorrow for all. Success and the ability to thrive demands that workplaces support and take seriously belonging and mental health.”

The program will be emceed by motivational humorist Jon Petz who will also host a fireside chat on mental health. Other highlights of the day include a session on “The Opioid Crisis & the Workforce: How You Can Help” presented by Andre Bailey, Dr. Kendall Cortelyou and Amber Addario of Project Opioid. GOSHRM Past President, Cheryl Brown Merriwether, and Executive Director of the International Center for Addiction and Recovery Education (ICARE), will moderate a panel on “Creating a Community of Care: Mental & Behavioral Health Trends for the Post-Pandemic Workforce”. Panelists include Tony Jenkins (Florida Blue), Dr. Nick Dewan (Guidewell) and Ashley Grimes (NAMI).

Visit GOSHRM’s website here for the complete speaker schedule.

GOSHRM Celebrates Award-Winning 2022 with Focus on Opioid Addiction in the Workplace

The Centers for Disease Control and Prevention (CDC) reports over 107,000 Americans died of an overdose in the 12 months ending December 2021. 70% of illicit drug users are employed, and 67% of HR managers admit that substance misuse is a serious problem in the workplace.

Motivated by these startling statistics, GOSHRM submitted for and won both SHRM’s 2022 Pinnacle Award and the HR Florida Chapter Excellence Award. These unprecedented accomplishments recognized GOSHRM at both the national and state level. The winning program was a collaborative effort between GOSHRM, ICARE, Project Opioid and CareerSource Central Florida to raise awareness and mitigate opioid addiction in the workforce.

Project Opioid partnered with CareerSource Central Florida (CSCF), a local workforce board, to provide training to local businesses in Central Florida. In March of 2021, CSCF launched “Fostering Opioid Recovery through Training & Employment” (FORTE). CSCF contracted with ICARE to design, develop and deliver the Certified Facilitator in Addiction Awareness for Human Resources (CFAA-HR) program. To ensure the success of this critical project, ICARE reached out to GOSHRM for assistance.

Covid was hugely challenging for GOSHRM, according to GOSHRM Past President Merriwether, “Being able to partner with other community-based organizations to impact individual lives, (and by extension families, workplaces and our community at large) helped us pull together, commit to, promote, participate in and celebrate our collaborative accomplishments,” she said. “Together we created something of significance that had a positive impact, that was recognized at both the state level by the HR Florida Chapter Excellence award and nationally by SHRM through the Pinnacle Award.”

The FORTE initiative continues into 2023, and as a result of the community collaboration, and has expanded beyond Central Florida to an international level.

GOSHRM President’s Vision for 2023

“My goal for GOSHRM is to guide the organization to be the leading HR point of contact for Central Florida to bring HR professionals and business leaders together to elevate the HR profession,” said GOSHRM President, McGee. “An example of this was our Pinnacle Award winning collaboration with Project Opioid, CareerSource Central Florida and ICARE. We will continue to look for other opportunities to collaborate and impact our community in 2023.”

About GOSHRM

GOSHRM was founded in 1957 as the Central Florida Human Resources Association (CFHRA). It is one of the 575 local affiliate chapters of SHRM, and one of 28 local chapters in the State of Florida. GOSHRM has more than 600 HR and related professional members who represent and provide support to small, medium and large size employers across multiple counties in Central Florida. GOSHRM’s Mission, Vision and Values are as follows:

MISSION – Elevate people and workplaces through education, connections and service.

VISION – Make Central Florida a workplace destination of choice.

VALUES – Offer Continuous Development to enhance each member’s role as trusted advisers and valued business partners.

GOSHRM encourages the active participation of members and promotes interaction between chapter members, from students to long-time industry professionals, in an effort to better connect the HR community in the Greater Orlando area. GOSHRM is the only Society for Human Resource Management affiliated chapter in the greater Orlando area. For more information visit http://www.goshrm.org.

# # #

Share article on social media or email:

ReferWell Closes Series B Funding to Accelerate Growth by Enhancing Care Navigation and Improving Access to Care


News Image

ReferWell, the digital health company focused on leveraging the “referable moment”SM to find and schedule patient care, today announced that it has closed its Series B funding round led by the healthcare private equity firm, Viewside Capital Partners.

Investors from Essen Ventures, the venture arm of Essen Health Care, a fully integrated healthcare delivery network in New York, joined existing investors Health Catalyst Capital and Connecticut Innovations in the funding round. Essen will deploy ReferWell across its entire organization encompassing more than 400 providers across nearly 50 locations.

Stephen Raggio, Co-Founder and Managing Partner of Viewside, stated “Referwell is on the leading edge of solving a persistent obstacle in a unique way – getting patients scheduled for the care they need with the right in-network provider. The payer, provider and hospital system markets are responding with aggressive uptake and we expect substantial continued growth in the future. Their organization has been built to scale, and the ReferWell team has deep experience and a proven track record. Viewside Capital is extremely excited to be a part of a solution that improves patient outcomes while also lowering the overall cost of care.”

ReferWell CEO Vytas Kisielius said the company will use the funds to continue to scale rapidly in a space historically limited by manual, time-intensive work. “ReferWell’s ability to tech-enable a complex task—navigating healthcare and scheduling appointments—is fundamental to every aspect of healthcare,” said Kisielius. “As a result, we’re adding many new payor and provider clients while our existing customers expand rapidly.”

ReferWell is gaining meaningful traction with Medicare and Medicaid health plans searching for efficient and effective member engagement strategies that help meet federal requirements. In targeted programs last year, ReferWell care navigators reached out to nearly 60,000 beneficiaries and recorded an impact rate up to ten-times higher than plan benchmarks.

ReferWell was founded in 2014 by a New York City-based cardiologist who wanted to make it easier for patients to receive follow-up care. While the company has entered additional markets and expanded the scope of its services, the original mission endures today: make it easy for patients to find and schedule appointments at the point-of-care (the original referable moment) and enable the sharing of patient clinical information between providers to enhance and simplify care coordination.

About ReferWell:

ReferWell is a digital health company focused on leveraging the referable momentSM — the point in time when a person is most ready to take action to improve their health – to improve access to care, increase health plans’ quality performance and reduce the total cost of care, all while improving members’ experience and outcomes. ReferWell’s intuitive technology platform and skilled service team helps health plans and providers manage value and help more people get on, and stay on, their healthcare journey. ReferWell, headquartered in Stamford, Connecticut, has grown to support plans responsible for more than 28 million covered lives across the U.S.

Share article on social media or email:

Physician Medical Group M&A Activity Decreases 11% in Q4:22, According to Data from Irving Levin Associates, LLC


News Image

“Higher interest rates impacted the final quarter, but investor interest is still high, and we anticipate that deal activity will bounce back in the first quarter of 2023.”

Merger and acquisition activity in the Physician Medical Group sector declined by 11% in Q4:22, according to data captured in LevinPro HC. Yet, the fourth quarter of 2022 had a 11% increase in activity compared with Q4:21 when 138 PMG acquisitions were announced. In addition to deal volume falling, announced spending in the fourth quarter of 2022 also declined. The only PMG deal to have a disclosed price was Digital Transformation Opportunities Corp.’s acquisition of American Oncology Network, LLC for $500 million. This is a significant decrease from Q3:22 with more than $786.2 million in disclosed prices across two deals.

The PMG subsector with the most activity was dental practices with 60 transactions, representing 39% of the total. This accounts for an approximately 28% decrease from Q3:22 when 83 dental deals were reported. The second-busiest specialty was eye care with 16 deals, a slight drop from the 22 eye care deals in Q3:22.

Keeping in line with past trends, private equity (PE) firms and their portfolio companies were responsible for most of the PMG activity, representing 67% of PMG deals in Q4:22 for a total of 102 transactions. PE activity this past quarter fell short of previous quarters. In Q3:22, PE buyer activity accounted for 72% of deals and Q4:21 accounted for 70% of deals.

“While PMG activity reported in Q4:22 is lower than the previous quarter, that doesn’t necessarily mean that PMG interest overall is declining. Higher interest rates impacted the final quarter, but investor interest is still high, and we anticipate that deal activity will bounce back in the first quarter of 2023,” said Glenn Kalinoski, Editor of Healthcare at Irving Levin Associates.

All quarterly results are published in The Health Care M&A Report, which is part of the Irving Levin Associates and LevinPro investment research source. For information, or to order the reports, call 800-248-1668. Irving Levin Associates is celebrating more than 70 years of delivering exclusive M&A intelligence to its sophisticated audience of seniors housing and healthcare investors. The company was established in 1948 and has offices in New Canaan, Connecticut, and North Bethesda, Maryland. The company publishes research reports and newsletters and maintains databases on the healthcare and senior housing M&A markets.

Share article on social media or email:

Patient Journey and Disease Progression — Exploring the Power of Images in Real-World Data, Upcoming Webinar Hosted by Xtalks


Imaging is a critical part of care and has untapped potential when linked with a data source such as EHR data that reveals other key patient demographics and characteristics.

Claims and electronic health record (EHR) data are known sources of real-world healthcare data — neither of which were created for real-world evidence (RWE) generation — but have proved effective in deeply understanding the patient journey. More recently, it has become evident that medical images, from histopathology slides, X-rays, CT scans to MRI scans and ophthalmic images, can offer RWE insights as well when linked with sources such as claims and EHR. Ophthalmic images, for example, capture fluid levels, lesion growth and visual field, all of which are critical in an ophthalmologist’s diagnosis, treatment and care decisions. These variables are just as relevant for researchers to identify patients for a clinical trial, track disease progression within patient populations or understand how patient groups responded to a certain treatment.

Imaging is a critical part of care and has untapped potential when linked with a data source such as EHR data that reveals other key patient demographics and characteristics. In order to use these images as a source of real-world data (RWD) — all of which exist in different formats — researchers are applying machine learning (ML) techniques and developing algorithms to label and recognize patterns.

Join this webinar to learn about the power of images, specifically ophthalmic images, and how linking them with EHR data and applying ML can help support patient journey and disease progression research.

Bonus: Hear use cases for imaging that include support for clinical trials, optimized dosing schedules and comparative effectiveness studies.

Join Aaron Y. Lee, MD MSCI, Associate Professor and Retina Surgeon, University of Washington, Department of Ophthalmology; Michael Mbagwu, MD, Senior Medical Director, Verana Health; and Zhongdi Chu, PhD, MSc, Quantitative Sciences, Verana Health, for the live webinar on Wednesday, January 25, 2023, at 1pm EST (10am PST).

For more information, or to register for this event, visit Patient Journey and Disease Progression — Exploring the Power of Images in Real-World Data.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Top NYC Plastic Surgeon, Announces Free Virtual Plastic Surgery Consultations


Matthew A. DelMauro, MD

Matthew A. DelMauro, MD

A growing number of patients are requesting remote care, which is why the Body Sculpting Center of NYC now offers virtual consultations.

The Body Sculpting Center of NYC (https://www.bodysculptingcenternyc.com), located in Manhattan, New York announced today that the body sculpting plastic surgery practice will now offer patients remote / telehealth consultations from anywhere in the world. Dr. Matthew DelMauro, founder and medical director of the Body Sculpting Center of NYC, observed “Since the genesis of the COVID-19 epidemic, there has been a consistent, unwavering need for virtual consultations at our clinic”.

“We understand that many of our patients continue to feel affected by the COVID-19 pandemic. In addition to in-person consultations, we want to offer telehealth consults from anywhere in the world to help ease our patients’ concerns and help them get the medical care they need. A growing number of patients are requesting remote care, which is why the Body Sculpting Center of NYC now offers virtual consultations.” The Body Sculpting Center of NYC’s team has closely monitored the consistent rise in requests for remote care, which is why the practice chose to offer patients virtual consultations in addition to in-person visits.

Harvard Business Review reports that at least 69% of adults in the U.S. employed audio and video telehealth technology to engage with practitioners and patients remotely in 2020. Our board certified Manhattan, New York based body sculpting plastic surgeon and his dedicated team strive to create body sculpting results that reflect the needs and unique anatomy of each patient. In order to give our patients, the safest and most practical medical care possible, our NYC based aesthetic plastic surgeon, Dr. Matthew DelMauro, now offers patients virtual consultations (from anywhere in the world).

As a board certified NYC based aesthetic plastic surgeon, Dr. DelMauro and his Manhattan based Body Sculpting Center of NYC team regularly administer virtual consultations with prospective aesthetic surgery patients from all over the world, in order to ensure each individual is comfortable and confident in their healthcare experience.

About Us

Unique to Manhattan and the surrounding NYC areas, Body Sculpting Center of NYC (a fully accredited plastic surgery center) merges the safety and effectiveness of a top rated plastic surgery practice with the tranquility and opulence of a modern spa. We are true concierge plastic surgery with the most competitive pricing in Manhattan, NY. Our board certified NYC plastic surgeons’ particular expertise includes minimally invasive liposuction (liposuction 360), breast implants and breast reductions, fat transfer to the hips, breast, and shoulders, mommy makeovers, tummy tucks, male liposuction and body contouring, buttock lifts (BBL), body lifts and arm lift plastic surgery.

Body Sculpting Center of NYC

590 5th Avenue

Suite 1106

New York, NY 10036

(646) 257-2677

https://www.bodysculptingcenternyc.com

Share article on social media or email: